Pfizer withdraws application for emergency use authorisation of its COVID-19 vaccine in India
In a statement, Pfizer said it had decided to withdraw the application after a meeting with the Drug Regulatory Authority of India on 3 Feb, in which the regulator stated that there may be need for 'additional information'
New Delhi: Pharma major Pfizer on Friday said it has decided to withdraw its application for Emergency Use Authorisation (EUA) of its COVID-19 vaccine in India.
Pfizer was the first pharmaceutical firm to seek an emergency use authorisation from the Drugs Controller General of India (DCGI) for its COVID-19 vaccine in the country, after it secured such clearance in the UK and Bahrain.
"In pursuance of the Emergency Use Authorisation of its COVID-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," a company spokesperson said in a statement.
Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future, the statement said.
"Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," the spokesperson said.
Pfizer in its application submitted to the drug regulator in December 2020, had sought permission to import the vaccine for sale and distribution in India, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, official sources had said.
Inequities in supply have become more pronounced, and demand for shots in the US — where nearly 64% of adults have received at least one jab — has dropped
A study by researchers at the NCDC and the CSIR IGIB has found that the second wave surge in cases in Delhi was mainly caused by the Delta variant
NITI Aayog's VK Paul said the issue has come up in the context of foreign companies, specifically Pfizer, and that the Centre is discussing the issue with the company